Full-Time

Vice President Value Demonstration and Economic Modeling

Precision AQ

Precision AQ

501-1,000 employees

Data-driven drug access and launches

Compensation Overview

$192k - $270k/yr

+ Bonus

Remote in USA

Remote

Remote within the United States.

Category
Biology & Biotech (1)
Required Skills
Public Policy
Biostatistics

Get referred to Precision AQ

See people who can refer or advise you

Requirements
  • 10-12+ years of experience, at least four in a consulting environment
  • Postgraduate degree - PhD, MD, or PharmD preferred; Master’s degree in a subject related to health services research (e.g., health economics, public policy, health policy, epidemiology, biostatistics, or public health), with relevant experiences considered.
  • Strong knowledge of the biopharmaceutical industry and payer-evidence requirements
  • Proven record of leadership experience in high-impact HEOR publications, business development, consulting, and/or leadership, including a proven track record of success.
  • Expert review and interpretation of data outputs and results, and develop/deliver publications and/or presentations
  • Experience with development of pharmacoeconomic models, with specific understanding of value-demonstration modeling, including but not limited to:
  • Possesses expert understanding of the biopharmaceutical industry, medical affairs, and requirements for payer and health-technology assessment, evidenced by a track record of relevant publications
  • Demonstrates sufficient understanding of relevant methods to be able to oversee studies involving model development/validation (budget impact, cost effectiveness, cost consequence, other), and utility modelling/mapping (trial-based analyses)
  • Clearly explains the rationale, methods/results, and strategy for studies to project teams, clients, and external stakeholders
  • Understands strengths and limitations of alternative approaches and proposes applications/solutions of new or existing methods tailored to a specific research question
  • Strong strategic and technical writing skills
  • Knowledge of the interconnectedness of the variety of commercialization services that a life sciences company needs to successfully launch a project.
Responsibilities
  • Actively participate in and contribute to the senior leadership of the business including setting business strategy, participating in initiatives that encourage colleague engagement and satisfaction, promoting business growth, and ensuring operational and methodological excellence
  • Collaborate across multiple business units on business strategy and execution
  • Provide leadership and direction as part of the core Evidence Generation and overall HEOR leadership team delivering high-quality evidence-strategy planning, economic modeling, real-world evidence, and related services to biopharmaceutical industry clients globally
  • Coordinate prioritization, resource allocation, and delivery for VDEM projects with resource and project leaders
  • Contribute to business growth within existing HEOR services and expansion of HEOR-related service lines
  • Achieve revenue and sales targets through direct client engagement, and support research and scientific leads in client management, project delivery, and sales activities
  • Build new business opportunities and maintain long-term partnerships with clients, proactively identifying and proposing technical and strategic solutions
  • Manage multiple assigned accounts simultaneously and related revenue
  • Manage communications to support department and business unit goals and objectives
  • Identify, develop and retain talent both inside and outside of the existing VDEM team
  • Partner with colleagues and business leaders on staffing-decision recommendations (level to hire/when to hire) based on capacity models, utilization, and business pipeline
  • Coach, mentor, and develop VDEM staff including overseeing new-employee onboarding and providing career development planning and opportunities
  • Empower employees to take responsibility for their career development and goals

Precision AQ helps pharmaceutical companies get FDA-approved medicines to patients by using data, evidence, and market insights to shape access and launches. Its services combine medical science, commercial strategy, and technology development to create new pathways for drug availability and timely delivery. The company partners with drug makers to plan launches and expansion, using analytical and creative approaches to make medicines reachable and effective in real-world settings. Unlike firms that focus only on science or marketing, Precision AQ blends data-driven insights with strategic execution across development and commercialization to accelerate patient access. The goal is to raise standards in healthcare accessibility and impact by getting the right medicines to the right patients faster.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

New York City, New York

Founded

N/A

Get referred to Precision AQ

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-enabled evidence and analytics can improve payer and HTA submissions.
  • EU expansion creates room for localized market access and launch support.
  • Cross-selling integrated commercialization services can expand revenue within existing accounts.

What critics are saying

  • U.S. Medicare Part B pricing pressure can shrink commercialization budgets quickly.
  • Biotech funding weakness delays launches, label expansions, and HEOR projects.
  • AI or evidence-synthesis errors can damage trust and trigger client losses.

What makes Precision AQ unique

  • Combines HEOR, market access, medical communications, and branding under one platform.
  • Recent hires deepen AI, data strategy, evidence synthesis, and decision modeling.
  • Works with all 30 top pharmaceutical companies and launched 450+ drugs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Parental Leave

Performance Bonus

Company News

PR Newswire
Feb 17th, 2026
Precision AQ expands leadership with AI and data strategy hires to strengthen global biopharma solutions

Precision AQ, a global life sciences commercialisation partner, has appointed two senior leaders to expand its AI and data capabilities. Emma Hawe joins as Senior Vice President, Managing Director for Evidence Synthesis & Decision Modelling, bringing over 25 years of experience in evidence generation and applied statistics. She currently chairs ISPOR's HEOR Excellence—Methodology Award. Yahya Shaikh becomes Senior Vice President, Data Strategy & AI, focusing on strengthening the company's data foundation and advancing AI-enabled solutions. He brings decades of experience in AI, analytics and enterprise data strategy across life sciences and healthcare. The appointments aim to bolster Precision AQ's presence in the EU whilst expanding its global reach. The company works with all 30 top pharmaceutical firms and has launched over 450 drugs across therapeutic areas.

StreetInsider
Nov 18th, 2025
Precision AQ Invests in Phluence Platform

Precision AQ has made a strategic investment in Phluence, enhancing its post-prescription capabilities. This investment allows pharmaceutical manufacturers to virtualize patient services, reduce costs, and improve access through Phluence's advanced agentic workflow management platform. The collaboration aims to modernize patient engagement with AI-driven solutions, offering an alternative to traditional HUB models. This move supports Precision AQ's goal to streamline patient services and accelerate access to therapies.

PR Newswire
Apr 25th, 2025
Precision Aq Expands Industry-Leading Access Experience Team (Aet) With Three Oncology Experts

-- Shraddha Kansagra, PharmD, BCOP, former Clinical Pharmacy Specialist at UT Southwestern, appointed Vice President, Clinical Oncology Solutions ---- Angelica Norrell, PharmD, BCOP, CSP, former Senior Director of Product at Optum, joins as Senior Director, AET ---- Courtney Patterson, PharmD, MBA, former System Director of Oncology Pharmacy Services at Advocate Health, joins as Vice President, Clinical Oncology Solutions --NEW YORK, April 25, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, today announced the additions of Shraddha Kansagra, PharmD, BCOP, Angelica Norrell, PharmD, BCOP, CSP, and Courtney Patterson, PharmD, MBA to its Access Experience Team (AET). These experts join Precision AQ's AET, an industry-leading team of former access decision-makers and influencers, to provide critical insights to life science companies and support them in anticipating payer challenges and designing strategies to optimize patient access in oncology.As access decisions in oncology increasingly incorporate both payer and provider perspectives, the additions of Drs. Kansagra, Norrell, and Patterson reflect Precision AQ's commitment to evolving with the landscape. Precision AQ's AET boasts numerous oncology experts, including five Board Certified Oncology Pharmacists (BCOPs), from prominent payer and provider-based institutions across the United States. These new additions further bolster the AET's expertise and capabilities, including driving medical and pharmacy benefit management for Value Based Care, drug coverage policy and formulary design; optimizing patient care through quality improvement initiatives; and overseeing pharmacy and healthcare operations."We are delighted to welcome Shraddha, Angie, and Courtney to Precision AQ, bolstering our AET with additional expertise in oncology, one of the most innovative areas in healthcare," said Chad Clark, President and Chief Operating Officer of Precision Medicine Group. "Together with our existing roster of top-tier access decision makers, as well as our external network of over 100 oncology advisors from leading U.S

PR Newswire
Mar 31st, 2025
Precision Aq Earns Hitrust Implemented, 1-Year I1 Certification For Data Protection And Cybersecurity Risk Management

HITRUST i1 certification confirms Precision AQ's commitment to protecting sensitive data with leading security practices.NEW YORK, March 31, 2025 /PRNewswire/ -- Precision AQ, a leader in guiding life science organizations through the complexities of product commercialization and empowering access to life-changing medicines for all, announced today that its PatientLens platform has achieved HITRUST certification for system and information security.PatientLens transforms healthcare insights and patient program design by reducing friction in patient services and by delivering timely, actionable information to support decision-making. The platform offers a detailed view of insurance coverage, out-of-pocket costs, and medical or medication history. By leveraging tokenized patient data and advanced analytics, PatientLens helps healthcare organizations optimize patient outreach, prioritize cases, and ensure compliance, driving improved outcomes and operational efficiency.The HITRUST Implemented, 1-Year i1 validated assessment and certification process confirms that the PatientLens platform applies a robust set of HITRUST-curated controls. These controls ensure the organization follows leading security practices and maintains a comprehensive cybersecurity program to defend against cyber threats. HITRUST continuously analyzes cyber threat intelligence to keep its control requirements relevant, helping organizations mitigate emerging risks like phishing, brute force attacks, and ransomware, and supporting organizational resilience."The HITRUST i1 validated assessment is a powerful tool for cyber-aware organizations, such as Precision AQ," said Robert Booker, Chief Strategy Officer at HITRUST. "This certification assures the measurement, implementation, and performance of robust information security controls

GlobeNewswire
Mar 4th, 2025
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...